Sari, RSevinc, ABuyukberber, S2024-08-042024-08-0420000003-3197https://doi.org/10.1177/000331970005100707https://hdl.handle.net/11616/93237Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease. It is rarely associated with severe bone marrow suppression. A case of an elderly woman is reported who developed febrile agranulocytosis two months after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with granulocyte colony-stimulating factor (G-CSF). All patients should have regular monitoring of their blood counts during therapy with ticlopidine.eninfo:eu-repo/semantics/closedAccessSevere Aplastic-AnemiaMechanismTherapyArticle5175915931091758310.1177/0003319700051007072-s2.0-0033941163Q2WOS:000088277700007Q4